# Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging

> **NCT03105609** · — · TERMINATED · sponsor: **Center for Eye Research Australia** · enrollment: 4 (actual)

## Conditions studied

- Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DEVICE:** Hyperspectral imaging

## Key facts

- **NCT ID:** NCT03105609
- **Lead sponsor:** Center for Eye Research Australia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-14
- **Primary completion:** 2018-12-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The delay between diagnosis and initiation of treatment was no longer consistent with standard of care
- **Last updated:** 2019-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03105609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03105609, "Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03105609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*